Shots: The P-lll RUXCOVID study involves assessing Ruxolitinib (5mg, bid) + SoC therapy vs PBO + SoC therapy in 432 patients aged ≥12 yrs. in a ratio (2:1) hospitalized for COVID-19 and not intubated or receiving ICU care prior to randomization The study did not meet its 1EPS of reducing the number of hospitalized COVID-19 […]Read More
Shots: The P-III RUXCOVID study involves assessing of ruxolitinib (5mg, bid) + SoC vs PBO + SoC in 400 patients in a ratio (2:1) aged ≥12 yrs. with COVID-19 associated cytokine storm. The study is sponsored by the Incyte in the US and Novartis outside the US The composite 1EP is the proportion of patients […]Read More
Copyright ©2021 PharmaShots | Powered by Octavus Consulting
